<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toxoplasmosis: Acute systemic disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toxoplasmosis: Acute systemic disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Toxoplasmosis: Acute systemic disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eskild Petersen, MD, DMSc, DTM&amp;H</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 23, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2873715833"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Toxoplasmosis, an infection with a worldwide distribution, is caused by the intracellular protozoan parasite, <em>Toxoplasma gondii</em>. Immunocompetent persons with primary infection are usually asymptomatic. However, in some immunocompetent individuals, <em>T. gondii</em> infection can present as an acute systemic infection or as ocular disease (eg, posterior uveitis). </p><p>After initial infection (even if asymptomatic), latent infection will persist for the life of the host. Immunocompromised individuals (eg, those with HIV/AIDS, transplant recipients) can have reactivation of latent infection; such patients typically present with multiple central nervous system abscess-like, round processes with ring enhancement.</p><p>This topic will discuss the clinical manifestations, diagnosis, and treatment of acute systemic disease in immunocompetent persons. Discussions of ocular toxoplasmosis, and toxoplasmosis in individuals with HIV, pregnant women, and neonates are presented separately. (See  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease"</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis"</a>.) </p><p class="headingAnchor" id="H4221365242"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H2661406668"><span class="h2">Genotypes</span><span class="headingEndMark"> — </span>There are three main <em>T. gondii</em> genotypes (types I, II, and III), which are prevalent in different geographic areas, and can impact the clinical presentation of <em>T. gondii</em> infection [<a href="#rid1">1</a>]. As an example, in Europe, where genotype II is present, 80 to 90 percent of individuals who become infected are asymptomatic. This is in contrast to South and Central America, where other genotypes are present, and infection is associated with a higher rate and increased severity of disease [<a href="#rid2">2-4</a>]. A mix of genotype I and II are the most prevalent in North America.</p><p class="headingAnchor" id="H962234413"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The seroprevalence of <em>T. gondii</em> infection ranges widely depending upon the geographic area. Seroepidemiologic surveys in the United States report that 11 percent of persons aged 6 to 49 are seropositive for <em>T. gondii</em> [<a href="#rid5">5</a>], whereas the seroprevalence is as high as 78 percent in some areas of Brazil [<a href="#rid6">6</a>]. </p><p>In the United States, the prevalence is higher in non-Hispanic Black persons compared with non-Hispanic White persons, and in persons born outside the United States. For persons aged 12 to 49 born in the United States, the seroprevalence declined from 14 to 9 percent between 1999 and 2004 [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H2723555736"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>Felines are the only animals in which <em>T. gondii</em> can complete its reproductive cycle [<a href="#rid7">7</a>]. Following feline ingestion of any of the forms of <em>T. gondii</em>, the parasite infects the gut epithelial cells and reproduces. The feline then excretes infectious oocysts in feces.</p><p>When non-felines (mammals and birds), including humans, ingest <em>T. gondii</em> oocysts, the organisms invade intestinal epithelium and disseminate throughout the body. They then encyst in any type of nucleated cell and lie dormant within tissues for the life of the host.</p><p>There are four means of acquiring toxoplasmosis in humans [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of infectious oocysts from the environment (usually from soil or fresh water sources contaminated with feline feces) or from contaminated fruits or vegetables</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of tissue cysts in meat from an infected animal </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vertical transmission from an infected mother to her fetus</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transmission through an organ transplantation from an infected donor</p><p></p><p>In most resource-limited settings, infection is typically acquired through environmental exposures, such as water from lakes and reservoirs, since meats are usually not eaten undercooked. However, ingestion of undercooked meat is responsible for the majority of toxoplasmosis cases in Asia, Europe, and the United States [<a href="#rid8">8-11</a>]. </p><p>In a case-control study that was conducted from 2002 to 2007 in the United States, a multivariate analysis found that <em>T. gondii</em> infection was associated with eating raw or undercooked foods (ground beef and lamb) and drinking unpasteurized goat's milk [<a href="#rid11">11</a>]. In addition, working with meat or owning three or more kittens was associated with an increased risk of infection. Eating undercooked venison is also a possible source in the United States [<a href="#rid12">12,13</a>]. </p><p class="headingAnchor" id="H1908642709"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Immunocompetent persons with primary infection are usually asymptomatic. However, in some immunocompetent hosts, <em>T. gondii</em> infection can present as an acute systemic infection, which typically develops 5 to 23 days after exposure to the organism [<a href="#rid14">14</a>]. Most immunocompetent patients who develop symptoms have a benign, self-limited course that typically lasts from a few weeks to months [<a href="#rid15">15-17</a>]. </p><p class="headingAnchor" id="H2424833953"><span class="h2">General symptoms</span><span class="headingEndMark"> — </span>Patients with acute toxoplasmosis typically present with constitutional symptoms, such as fever, chills, and sweats; however, these symptoms are generally mild, and the febrile episodes usually last two to three days. Headaches, myalgias, pharyngitis, hepatosplenomegaly, and/or a diffuse non-pruritic maculopapular rash may also occur.</p><p class="headingAnchor" id="H3297233650"><span class="h2">Lymphadenopathy</span><span class="headingEndMark"> — </span>The most common clinical manifestation of acute toxoplasmosis is bilateral, symmetrical, nontender cervical adenopathy [<a href="#rid18">18</a>]. Approximately 20 to 30 percent develop generalized lymphadenopathy. The lymph nodes are usually smaller than 3 centimeters in size and are nonfluctuant. Unlike the fever, which lasts for a short duration, lymphadenopathy can persist for weeks. (See  <a class="medical medical_review" href="/z/d/html/8386.html" rel="external">"Evaluation of peripheral lymphadenopathy in adults"</a>.) </p><p class="headingAnchor" id="H1070155460"><span class="h2">Uncommon manifestations</span><span class="headingEndMark"> — </span>On rare occasions, immunocompetent patients may present with severe disease such as pneumonitis [<a href="#rid19">19</a>], acute respiratory distress syndrome, myocarditis [<a href="#rid20">20-22</a>], pericarditis [<a href="#rid23">23</a>], polymyositis [<a href="#rid24">24,25</a>], hepatitis, posterior uveitis, or encephalitis.</p><p class="headingAnchor" id="H2463140069"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Laboratory findings are nonspecific in patients with toxoplasmosis. Patients may have a slight lymphocytosis with or without atypical cells. If atypical lymphocytes are present, they usually account for less than 10 percent of the total leukocyte count. Hepatic transaminases may also be slightly elevated, and there may be moderate increases in the C-reactive protein.</p><p class="headingAnchor" id="H743537681"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of toxoplasmosis should be considered in immunocompetent hosts who present with an acute onset of fever and lymphadenopathy. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H1335575193"><span class="h2">Serologic testing</span><span class="headingEndMark"> — </span>Serologic testing is typically used to determine if a patient has toxoplasmosis. An enzyme-linked immunosorbent assay (ELISA) is most commonly used due to overall performance and cost. In acute infection, IgM antibodies usually appear within one week of symptom onset and continue to rise. Toxoplasma-specific IgG antibodies subsequently follow within approximately two weeks of primary infection, peak within approximately eight weeks, and generally persist for life. </p><p class="bulletIndent1"><span class="glyph">●</span>For most patients, the diagnosis is eliminated if the patient has no evidence of either IgM or IgG antibodies. However, for those who present within one week of symptom onset, a repeat test should be performed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient has IgM antibodies detected without the presence of IgG antibodies, the diagnosis of newly acquired toxoplasmosis is likely. However, a positive IgG antibody obtained approximately two weeks later is needed to confirm the diagnosis. The IgM-antibody reaction is usually considered a false-positive if IgM antibodies persist without the development of IgG antibodies after three weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If serial testing of two samples two weeks apart is not enough to establish whether the patient has had a recent infection, samples can be analyzed with an IgG-avidity assay. DNA amplification of toxoplasma using PCR testing of blood can also confirm acute infection; however, the sensitivity varies and may be as low as 53 percent in patients with acute toxoplasmic lymphadenopathy, as parasites disappear from the peripheral circulation [<a href="#rid26">26</a>].</p><p></p><p>A more detailed discussion of serologic testing is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14003.html" rel="external">"Diagnostic testing for toxoplasmosis infection", section on 'Serologic testing'</a>.)</p><p class="headingAnchor" id="H2158338171"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Histopathologic examination of lymph nodes typically reveals follicular hyperplasia, focal distension of sinuses with monocytoid cells, and irregular clusters of tissue macrophages with eosinophilic cytoplasm [<a href="#rid18">18,27</a>]. Granulomata and abscesses are not seen. </p><p>Tachyzoites have been identified on fine needle aspiration specimens from patients with toxoplasmic lymphadenitis [<a href="#rid28">28</a>]. Although tachyzoites are difficult to demonstrate with standard stains, they may be observed with immunoperoxidase or fluorescent antibody stains. Parasites may also be detectable with DNA amplification by polymerase chain reaction (PCR) [<a href="#rid29">29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/14003.html" rel="external">"Diagnostic testing for toxoplasmosis infection", section on 'Polymerase chain reaction assays'</a>.)</p><p class="headingAnchor" id="H3881726388"><span class="h2">Differential diagnosis of acute systemic infection</span><span class="headingEndMark"> — </span>Approximately 1 percent of acute Epstein-Barr virus (EBV)-seronegative mononucleosis syndromes are due to toxoplasmosis [<a href="#rid31">31</a>]. Thus, acute toxoplasmosis should be considered in the differential diagnosis of patients who present with fever and adenopathy. </p><p>Alternative diagnoses include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus infection</strong> – Acute toxoplasmosis and EBV infection can both present with adenopathy and atypical lymphocytosis. However, patients with EBV are more likely to present with pharyngitis and tonsillitis. The diagnosis for both infections is typically made through serologic testing. (See  <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">"Infectious mononucleosis"</a> and  <a class="medical medical_review" href="/z/d/html/8283.html" rel="external">"Clinical manifestations and treatment of Epstein-Barr virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytomegalovirus infection</strong> – Both toxoplasmosis and cytomegalovirus (CMV) infection can cause a mononucleosis-like syndrome in immunocompetent adults. However, enlarged cervical nodes are not as common in patients with CMV disease. Serologic testing is typically used to diagnose CMV infection in this setting. (See  <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute HIV infection</strong> – Many of the symptoms of acute toxoplasmosis overlap with the symptoms of acute HIV infection (eg, fever and generalized lymphadenopathy). Early HIV infection should be suspected in patients who have had a recent high-risk exposure (eg, unsafe sexual contacts or needle sharing); however, the absence of elicited risk factors cannot preclude the possibility of HIV infection since some patients may not disclose this information. Diagnostic testing for acute HIV infection generally includes the use of a combination antigen/antibody immunoassay as well as a measurement of the HIV viral load. (See  <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tularemia</strong> – Tularemia should be considered in patients with fever and adenopathy if they are at risk of exposure to <em>Francisella tularensis (</em>eg, farmers, veterinarians, hunters, landscapers, and meat handlers). However, unlike toxoplasmosis where the adenopathy is typically bilateral and nontender, patients with glandular tularemia generally have tender regional lymphadenopathy involving single or multiple nodes. The diagnosis of tularemia is based upon serologic testing. (See  <a class="medical medical_review" href="/z/d/html/3141.html" rel="external">"Tularemia: Clinical manifestations, diagnosis, treatment, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cat scratch disease</strong> – Cat scratch disease (CSD) due to <em>Bartonella henselae</em> should be considered in individuals (particularly children) with fever and adenopathy. However, unlike toxoplasmosis, the lymph nodes are almost always tender, have erythema of the overlying skin, and are occasionally suppurative. In addition, the location of the lymphadenopathy depends on the site of the inoculation; the most common locations are the axillary, epitrochlear, cervical, supraclavicular, and submandibular lymph nodes. Serology is typically used to diagnose CSD. (See  <a class="medical medical_review" href="/z/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis</strong> – Tuberculosis should be considered in patients who present with cervical lymphadenopathy and fever. Patients with tuberculosis typically have a chronic presentation, and the physical examination reveals a firm, discrete mass or matted nodes fixed to surrounding structures; the overlying skin may be indurated. Diagnosis of tuberculous lymphadenitis is established by histopathology examination along with acid-fast bacilli smear and culture of lymph node material. (See  <a class="medical medical_review" href="/z/d/html/8001.html" rel="external">"Tuberculous lymphadenitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninfectious causes</strong> – Other considerations in the differential diagnosis include noninfectious diseases such as sarcoidosis, Hodgkin disease, and lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis"</a>.) </p><p></p><p class="headingAnchor" id="H1043334211"><span class="h1">TREATMENT OF ACUTE INFECTION</span></p><p class="headingAnchor" id="H2357684784"><span class="h2">Whom to treat</span><span class="headingEndMark"> — </span>Acute toxoplasmosis is typically self-limited, and most immunocompetent, nonpregnant adults do not require treatment [<a href="#rid32">32</a>]. However, we suggest treatment for those with severe or prolonged symptoms (eg, beyond a few weeks) and those with evidence of pneumonitis, myocarditis, meningoencephalitis, posterior uveitis, or polymyositis [<a href="#rid33">33,34</a>]. The management of immunocompromised hosts and pregnant women, as well as those with ocular disease, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease"</a>.) </p><p>There are limited data to support the benefit of treatment in immunocompetent patients with systemic infection [<a href="#rid35">35</a>]. The best evidence comes from a randomized trial of 46 patients with toxoplasmic lymphadenitis, where patients received <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX; an alternative agent for the treatment of toxoplasmosis) or placebo for one month. At the end of treatment, patients treated with TMP-SMX were more likely to have a clinical and serologic response (ie, resolution of adenopathy and IgM &lt;6 international units) compared with those who received placebo (65 versus 13 percent) [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H3303953389"><span class="h2">Choice of regimen</span><span class="headingEndMark"> — </span>The antimicrobial regimens used to treat immunocompetent individuals are the same as those used in immunocompromised patients; however, the duration is shorter. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a>.) </p><p>One of the following oral regimens is typically administered for two to four weeks:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">Pyrimethamine</a> (100 mg loading dose followed by 25 to 50 mg daily) plus <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> (2 to 4 grams daily in four divided doses) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> calcium (10 to 25 mg daily) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">Pyrimethamine</a> (100 mg loading dose followed by 25 to 50 mg daily) plus <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> (300 mg four times daily) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> calcium (10 to 25 mg daily) </p><p></p><p>If <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> is not available, TMP-SMX (5 mg/kg <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> and 25 mg/kg sulfamethoxazole given intravenously or orally twice daily; dosing is based upon the trimethoprim component) can be administered for two to four weeks. Studies in patients with lymphadenitis and ocular disease support the use of TMP-SMX as an alternative agent [<a href="#rid36">36</a>]. More detailed information on the use of TMP-SMX for the treatment of ocular disease is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease"</a>.)</p><p>In patients with a sulfonamide allergy, <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a> alone (750 mg four times daily) should be initiated, and sulfa desensitization should be attempted in those <strong>without</strong> a history of a severe reaction (eg, Stevens Johnson Syndrome) (see  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients"</a>). Such patients can subsequently be transitioned to TMP-SMX. </p><p>Other alternative regimens include a two- to four-week course of:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">Pyrimethamine</a> (100 mg loading dose followed by 25 to 50 mg daily) plus <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a> (750 mg four times daily) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> calcium (10 to 25 mg daily)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">Pyrimethamine</a> (100 mg loading dose followed by 25 to 50 mg daily) plus <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg daily) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> calcium (10 to 25 mg daily) </p><p></p><p>Monitoring for adverse drug reactions is discussed below. (See <a class="local">'Monitoring for adverse drug reactions'</a> below.)</p><p class="headingAnchor" id="H3214758507"><span class="h2">Monitoring for adverse drug reactions</span><span class="headingEndMark"> — </span>For patients with acute infection who receive a short course of treatment (eg, two weeks), we do not perform laboratory testing to monitor for adverse reactions. However, for those who require more prolonged therapy, it is important to obtain a complete blood count and metabolic profile after two weeks [<a href="#rid37">37</a>]. </p><p>Common side effects of <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> include rash, nausea, and bone marrow suppression. Higher doses of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, up to 50 to 100 mg daily, can be administered to manage hematologic abnormalities [<a href="#rid38">38</a>]. Sulfa-containing agents can lead to rash, fever, leukopenia, hepatitis, nausea, vomiting, diarrhea, crystalluria, and rarely, more severe reactions such as Stevens-Johnson syndrome. <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> can lead to fever, rash, and nausea; clindamycin is also associated with diarrhea related to production of <em>Clostridium difficile</em> toxin. Additional information can be found in the individual drug information topics within UpToDate.</p><p class="headingAnchor" id="H3030062507"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The risk of human toxoplasmosis can be reduced by taking the following precautions:</p><p class="bulletIndent1"><span class="glyph">●</span>Cook meats to adequate temperatures (meat 145°F/63°C, ground meat 160°F/71°C, poultry 165°F/74°C).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the meat is not going to be adequately cooked (ie, served rare), it should be frozen at subzero temperatures for several days. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wash cutting boards and/or other kitchen utensils with hot water and soap after contact with raw meat or shellfish and greens from the garden.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid unpasteurized non-bovine milk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wear gloves and/or wash hands with soap and water when there is contact with soil or sand that could be contaminated with cat feces.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wear gloves and/or wash hands with soap and water when there is contact with the cat litter of cats that forage outdoors or eat raw meat. Indoor house cats that are fed dry or canned processed cat food do not pose a risk.</p><p></p><p class="headingAnchor" id="H825323881"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113063.html" rel="external">"Society guideline links: Toxoplasmosis"</a>.)</p><p class="headingAnchor" id="H3641821527"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Toxoplasmosis is caused by the intracellular protozoan parasite, <em>Toxoplasma gondii</em>, and has a worldwide distribution. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are three main <em>T. gondii</em> genotypes (types I, II, and III), which are prevalent in different geographic areas, and can impact the clinical presentation of <em>T. gondii</em> infection. (See <a class="local">'Genotypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The seroprevalence ranges widely depending upon the geographic area. Seroepidemiologic surveys in the United States report that 11 percent of persons aged 6 to 49 are seropositive for <em>T. gondii</em>, whereas the seroprevalence is as high as 78 percent in some areas of Brazil. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are four means of acquiring toxoplasmosis in humans: ingestion of infectious oocysts from the environment, ingestion of tissue cysts in meat from an infected animals or from contaminated fruits or vegetables, vertical transmission from an infected mother to her fetus, and transmission through an organ transplantation from an infected donor. (See <a class="local">'Transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompetent persons with primary infection are usually asymptomatic. However, in some immunocompetent hosts, <em>T. gondii</em> infection can present as an acute systemic infection, which typically develops 5 to 23 days after exposure to the organism. Such patients typically present with constitutional symptoms and bilateral, symmetrical, nontender cervical adenopathy. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serologic testing is typically used to confirm the diagnosis. However, if a lymph node aspiration or biopsy is performed as part of the diagnostic evaluation, tachyzoites can be identified with immunoperoxidase or fluorescent antibody stains. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most immunocompetent, nonpregnant adults do not require treatment for acute infection since the disease is typically self-limited. However, we suggest treatment for those with severe or prolonged symptoms (eg, beyond a few weeks) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Whom to treat'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If treatment is indicated for acute systemic infection, a pyrimethamine-containing regimen (with either <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> or <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>) is typically preferred. However, if <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> is not available, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> can be administered. The duration of treatment is usually two to four weeks. (See <a class="local">'Choice of regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of human toxoplasmosis can be reduced by taking precautions to avoid exposure to <em>T. gondii</em>. (See <a class="local">'Prevention'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dardé ML. Toxoplasma gondii, "new" genotypes and virulence. Parasite 2008; 15:366.</a></li><li><a class="nounderline abstract_t">Ferreira IM, Vidal JE, de Mattos Cde C, et al. Toxoplasma gondii isolates: multilocus RFLP-PCR genotyping from human patients in Sao Paulo State, Brazil identified distinct genotypes. Exp Parasitol 2011; 129:190.</a></li><li><a class="nounderline abstract_t">Silveira C, Muccioli C, Holland GN, et al. Ocular Involvement Following an Epidemic of Toxoplasma gondii Infection in Santa Isabel do Ivaí, Brazil. Am J Ophthalmol 2015; 159:1013.</a></li><li><a class="nounderline abstract_t">Lindsay DS, Dubey JP. Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis. Parasitology 2011; 138:1829.</a></li><li><a class="nounderline abstract_t">Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am J Trop Med Hyg 2007; 77:405.</a></li><li><a class="nounderline abstract_t">Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009; 39:1385.</a></li><li><a class="nounderline abstract_t">Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30:1217.</a></li><li><a class="nounderline abstract_t">Baril L, Ancelle T, Goulet V, et al. Risk factors for Toxoplasma infection in pregnancy: a case-control study in France. Scand J Infect Dis 1999; 31:305.</a></li><li><a class="nounderline abstract_t">Rai SK, Matsumura T, Ono K, et al. High Toxoplasma seroprevalence associated with meat eating habits of locals in Nepal. Asia Pac J Public Health 1999; 11:89.</a></li><li><a class="nounderline abstract_t">Cook AJ, Gilbert RE, Buffolano W, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ 2000; 321:142.</a></li><li><a class="nounderline abstract_t">Jones JL, Dargelas V, Roberts J, et al. Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis 2009; 49:878.</a></li><li><a class="nounderline abstract_t">Sacks JJ, Delgado DG, Lobel HO, Parker RL. Toxoplasmosis infection associated with eating undercooked venison. Am J Epidemiol 1983; 118:832.</a></li><li><a class="nounderline abstract_t">England JH, Bailin SS, Gehlhausen JR, Rubin DH. Toxoplasmosis: The Heart of the Diagnosis. Open Forum Infect Dis 2019; 6:ofy338.</a></li><li><a class="nounderline abstract_t">Demar M, Hommel D, Djossou F, et al. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. Clin Microbiol Infect 2012; 18:E221.</a></li><li><a class="nounderline abstract_t">O'Connell S, Guy EC, Dawson SJ, et al. Chronic active toxoplasmosis in an immunocompetent patient. J Infect 1993; 27:305.</a></li><li><a class="nounderline abstract_t">Neves ES, Bicudo LN, Curi AL, et al. Acute acquired toxoplasmosis: clinical-laboratorial aspects and ophthalmologic evaluation in a cohort of immunocompetent patients. Mem Inst Oswaldo Cruz 2009; 104:393.</a></li><li><a class="nounderline abstract_t">Johnson JD, Holliman RE. Incidence of toxoplasmosis in patients with glandular fever and in healthy blood donors. Br J Gen Pract 1991; 41:375.</a></li><li><a class="nounderline abstract_t">McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis 1987; 9:754.</a></li><li><a class="nounderline abstract_t">Leal FE, Cavazzana CL, de Andrade HF Jr, et al. Toxoplasma gondii pneumonia in immunocompetent subjects: case report and review. Clin Infect Dis 2007; 44:e62.</a></li><li><a class="nounderline abstract_t">Montoya JG, Jordan R, Lingamneni S, et al. Toxoplasmic myocarditis and polymyositis in patients with acute acquired toxoplasmosis diagnosed during life. Clin Infect Dis 1997; 24:676.</a></li><li><a class="nounderline abstract_t">Chandenier J, Jarry G, Nassif D, et al. Congestive heart failure and myocarditis after seroconversion for toxoplasmosis in two immunocompetent patients. Eur J Clin Microbiol Infect Dis 2000; 19:375.</a></li><li><a class="nounderline abstract_t">Franco-Paredes C, Rouphael N, Méndez J, et al. Cardiac manifestations of parasitic infections. Part 2: Parasitic myocardial disease. Clin Cardiol 2007; 30:218.</a></li><li><a class="nounderline abstract_t">Cunningham T. Pancarditis in acute toxoplasmosis. Am J Clin Pathol 1982; 78:403.</a></li><li><a class="nounderline abstract_t">Behan WM, Behan PO, Draper IT, Williams H. Does Toxoplasma cause polymyositis? Report of a case of polymyositis associated with toxoplasmosis and a critical review of the literature. Acta Neuropathol 1983; 61:246.</a></li><li><a class="nounderline abstract_t">Calore EE, Minkovski R, Khoury Z, et al. Skeletal muscle pathology in 2 siblings infected with Toxoplasma gondii. J Rheumatol 2000; 27:1556.</a></li><li><a class="nounderline abstract_t">Angel SO, Matrajt M, Margarit J, et al. Screening for active toxoplasmosis in patients by DNA hybridization with the ABGTg7 probe in blood samples. J Clin Microbiol 1997; 35:591.</a></li><li><a class="nounderline abstract_t">Dorfman RF, Remington JS. Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. N Engl J Med 1973; 289:878.</a></li><li><a class="nounderline abstract_t">Zaharopoulos P. Demonstration of parasites in toxoplasma lymphadenitis by fine-needle aspiration cytology: report of two cases. Diagn Cytopathol 2000; 22:11.</a></li><li><a class="nounderline abstract_t">Weiss LM, Chen YY, Berry GJ, et al. Infrequent detection of Toxoplasma gondii genome in toxoplasmic lymphadenitis: a polymerase chain reaction study. Hum Pathol 1992; 23:154.</a></li><li><a class="nounderline abstract_t">Dai L, Huang J, Tang Y, et al. [Roles of histologic examination and polymerase chain reaction in diagnosis of toxoplasmic lymphadenitis]. Zhonghua Bing Li Xue Za Zhi 2010; 39:361.</a></li><li><a class="nounderline abstract_t">REMINGTON JS, BARNETT CG, MEIKEL M, LUNDE MN. Toxoplasmosis and infectious mononucleosis. Arch Intern Med 1962; 110:744.</a></li><li><a class="nounderline abstract_t">Dunay IR, Gajurel K, Dhakal R, et al. Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice. Clin Microbiol Rev 2018; 31.</a></li><li><a class="nounderline abstract_t">Georgiev VS. Management of toxoplasmosis. Drugs 1994; 48:179.</a></li><li><a class="nounderline abstract_t">Holland GN, Muccioli C, Silveira C, et al. Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis. Am J Ophthalmol 1999; 128:413.</a></li><li><a class="nounderline abstract_t">Rajapakse S, Chrishan Shivanthan M, Samaranayake N, et al. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health 2013; 107:162.</a></li><li><a class="nounderline abstract_t">Alavi SM, Alavi L. Treatment of toxoplasmic lymphadenitis with co-trimoxazole: double-blind, randomized clinical trial. Int J Infect Dis 2010; 14 Suppl 3:e67.</a></li><li><a class="nounderline abstract_t">Ben-Harari RR, Goodwin E, Casoy J. Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review. Drugs R D 2017; 17:523.</a></li><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguideline s/adult_oi.pdf (Accessed on March 04, 2016).</li></ol></div><div id="topicVersionRevision">Topic 120887 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814708" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Toxoplasma gondii, "new" genotypes and virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741380" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Toxoplasma gondii isolates: multilocus RFLP-PCR genotyping from human patients in Sao Paulo State, Brazil identified distinct genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25743340" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ocular Involvement Following an Epidemic of Toxoplasma gondii Infection in Santa Isabel do Ivaí, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21902872" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17827351" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433092" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113252" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Toxoplasma gondii: from animals to humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482062" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk factors for Toxoplasma infection in pregnancy: a case-control study in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11195164" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High Toxoplasma seroprevalence associated with meat eating habits of locals in Nepal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894691" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663709" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk factors for Toxoplasma gondii infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650484" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Toxoplasmosis infection associated with eating undercooked venison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30631794" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxoplasmosis: The Heart of the Diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21958195" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8308325" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic active toxoplasmosis in an immunocompetent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19430671" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute acquired toxoplasmosis: clinical-laboratorial aspects and ophthalmologic evaluation in a cohort of immunocompetent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1793647" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence of toxoplasmosis in patients with glandular fever and in healthy blood donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3326123" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17304443" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Toxoplasma gondii pneumonia in immunocompetent subjects: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145743" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Toxoplasmic myocarditis and polymyositis in patients with acute acquired toxoplasmosis diagnosed during life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898141" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Congestive heart failure and myocarditis after seroconversion for toxoplasmosis in two immunocompetent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17492686" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiac manifestations of parasitic infections. Part 2: Parasitic myocardial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7113981" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pancarditis in acute toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650138" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Does Toxoplasma cause polymyositis? Report of a case of polymyositis associated with toxoplasmosis and a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852291" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Skeletal muscle pathology in 2 siblings infected with Toxoplasma gondii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041395" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Screening for active toxoplasmosis in patients by DNA hybridization with the ABGTg7 probe in blood samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4580783" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10613965" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Demonstration of parasites in toxoplasma lymphadenitis by fine-needle aspiration cytology: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740299" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Infrequent detection of Toxoplasma gondii genome in toxoplasmic lymphadenitis: a polymerase chain reaction study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21055150" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Roles of histologic examination and polymerase chain reaction in diagnosis of toxoplasmic lymphadenitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13981595" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Toxoplasmosis and infectious mononucleosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30209035" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7527323" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Management of toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10577581" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816507" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antibiotics for human toxoplasmosis: a systematic review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194044" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of toxoplasmic lymphadenitis with co-trimoxazole: double-blind, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28879584" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
